Combretastatin Derivatives as Tubulin Inhibitors: A Fascinating Journey from Nature to Drug Discovery Strategies

Author:

Ammazzalorso Alessandra1,Hansen Trond Vidar2

Affiliation:

1. G. d’Annunzio University of Chieti,Department of Pharmacy, Medicinal Chemistry Unit,Pescara, via dei Vestini, 66100 Chieti,Italy

2. University of Oslo,Department of Pharmacy, Section for Pharmaceutical Chemistry,PO Box 1068 Blindern, N-0316,Oslo,Norway

Abstract

The combretastatins are a family of stilbene phenolic natural products isolated from the bark of the South African bush willow tree Combretum caffrum. Since their isolation and structural elucidation, these molecules have attracted a lot of interest due to their potent cytotoxic activity against several human cancer cell lines. Combretastatin A-4, a cis-stilbene, is the most potent member of these natural products, has the ability to strongly inhibit tubulin polymerization, resulting in high cytotoxic activity. Indeed, it also displays an additional activity as a potent vascular disrupting agent. This interesting double bioactive profile accounts for the potent antiproliferative and antivascular action in tumors. However, combretastatin A-4, due to the sensitive cis-stilbene moiety, is prone to isomerization giving the less bioactive trans-isomer and exhibits diminished water solubility. Hence, a wide panel of synthetic derivatives were therefore developed with the aim of overcoming these limitations. The development of prodrugs such as fosbretabulin, ombrabulin and Oxi4503 isrepresentative of successful attempts to overcome pharmacokinetic disadvantages, whereas the most recent approaches aim to develop combretastatin prodrugs able to selectively target tumor site, possessing also theranostic properties. Herein, miscellaneous and the most potent synthetic analogues are presented. In addition, a general outlook on combretastatin derivatives and drug delivery approaches based on innovative nanoformulations is also presented.

Publisher

BENTHAM SCIENCE PUBLISHERS

Reference81 articles.

1. Pettit G.R.; Singh S.B.; Niven M.L.; Hamel E.; Schmidt J.M.; Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 1987,50(1),119-131

2. Pettit G.R.; Singh S.B.; Schmidt J.M.; Nixen M.L.; Hamel E.; Lin C.M.; Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from Combretum caffrum. J Nat Prod 1988,51(3),517-527

3. Pettit G.R.; Singh S.B.; Hamel E.; Lin C.M.; Alberts D.S.; Garcia-Kendal D.; Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989,45(2),209-211

4. Lin C.M.; Singh S.B.; Chu P.S.; Dempcy R.O.; Schmidt J.M.; Pettit G.R.; Hamel E.; Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988,34(2),200-208

5. Dark G.G.; Hill S.A.; Prise V.E.; Tozer G.M.; Pettit G.R.; Chaplin D.J.; Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997,57(10),1829-1834

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3